ViewRay Announces 510(k) Pending Status of the Newest Generation of MRIdian Innovations
UF startup ViewRay, Inc., a leading medical technology company that provides groundbreaking MRI-guided radiation therapy, announced that the company has received acceptance from the FDA on their recent submission for new MRIdian features focused on enhancing on-table adaptive workflow efficiency and expanding clinical utility. ViewRay will be exhibiting at the annual ASTRO 2021 conference in Chicago, IL from October 24― October 26, 2021, and will be highlighting the new technological advancements during the conference.
ViewRay’s 510(k) pending submission consists of features including new MRI imaging sequences, automated workflow steps, on-table auto-contouring tools, multi-planar tissue tracking and automated beam gating, and the ability for clinicians to work collaboratively during patient treatments. The submission also includes a new brain treatment package and the integration of a real-time patient feedback display.
“We are pleased to announce this significant milestone in our development roadmap. ViewRay continues to be the leading innovator of MR-guided radiation therapy by now offering a new suite of features including multi-planar tissue tracking which enhances our industry-unique automatic beam gating technology”, said Scott Drake, ViewRay president and CEO, “As the number of MRIdian programs expands globally, customers have reinforced that they desire faster treatment times and expanding MRIdian treatments to additional disease sites. The technology submitted in our 510(k) is intended to address these customer requests.”
Learn more about ViewRay Announces 510(k) Pending Status of the Newest Generation of MRIdian Innovations.